Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

Not specified

Study Completion Date

December 31, 2005

Conditions

Hormone-refractory Prostate Cancer

Interventions

DRUG

ILX651

Trial Locations (12)

Cancer Care Northwest, Spokane

Arizona Clinical Research Center, Tucson

Kansas City Cancer Centers, Lenexa

Kansas City Cancer Centers, Overland Park

Kansas City Cancer Centers- Central, Kansas City

Cancer Center of North Carolina- Cary, Cary

Oregon Health and Science University, Portland

Sammons Cancer Center, Dallas

Texas Cancer Center at Medical City, Dallas

Joe Arrington Cancer Center, Lubbock

North Texas Regional Cancer Center, Plano

Swedish Cancer Institute, Seattle

All Listed Sponsors

lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00082134 - Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel | Biotech Hunter | Biotech Hunter